MX2020010302A - Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares. - Google Patents

Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.

Info

Publication number
MX2020010302A
MX2020010302A MX2020010302A MX2020010302A MX2020010302A MX 2020010302 A MX2020010302 A MX 2020010302A MX 2020010302 A MX2020010302 A MX 2020010302A MX 2020010302 A MX2020010302 A MX 2020010302A MX 2020010302 A MX2020010302 A MX 2020010302A
Authority
MX
Mexico
Prior art keywords
amino
carboxylic acid
eye disorders
difluoromethylidene
cyclopent
Prior art date
Application number
MX2020010302A
Other languages
English (en)
Spanish (es)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2020010302A publication Critical patent/MX2020010302A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2020010302A 2018-03-29 2019-03-29 Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares. MX2020010302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650004P 2018-03-29 2018-03-29
PCT/US2019/024726 WO2019191525A1 (en) 2018-03-29 2019-03-29 Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders

Publications (1)

Publication Number Publication Date
MX2020010302A true MX2020010302A (es) 2021-01-08

Family

ID=68056529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010302A MX2020010302A (es) 2018-03-29 2019-03-29 Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.

Country Status (10)

Country Link
US (1) US20190298674A1 (https=)
EP (1) EP3758693A4 (https=)
JP (1) JP2021519753A (https=)
KR (1) KR20210009306A (https=)
CN (1) CN112218628A (https=)
AU (1) AU2019243586A1 (https=)
CA (1) CA3095468A1 (https=)
IL (1) IL277599A (https=)
MX (1) MX2020010302A (https=)
WO (1) WO2019191525A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR202021080A2 (tr) * 2020-12-21 2022-07-21 Marmara Ueniversitesi Thi̇el-behnke kornea di̇strofi̇si̇ (tbkd) i̇çi̇n bi̇r yöntem ve söz konusu yöntem i̇le üreti̇len bi̇r yapay doku i̇skelesi̇
EP4482478A4 (en) * 2022-02-27 2026-03-04 Univ Northwestern (3S,4R)-3-AMINO-4-(DIFLUOROMETHYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS USED AS SELECTIVE ORNITHIN AMINOTRANSFERASE ACTIVATORS
KR20250034134A (ko) * 2022-07-06 2025-03-10 오비드 테라퓨틱스 인크. 암 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸렌일)사이클로펜트-1-엔-1-카르복실산의 사용
US20240285565A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes
JP2026506097A (ja) * 2023-02-17 2026-02-20 オービッド・セラピューティクス・インコーポレイテッド 多発性硬化症の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペント－１－エン－１－カルボン酸の使用
US20240285563A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
CA2790820A1 (en) * 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
EP2806867A4 (en) * 2012-01-27 2015-09-02 Catalyst Pharmaceutical Partners Inc METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS
ES2882126T3 (es) * 2014-11-07 2021-12-01 Univ Northwestern Inhibición de ornitina aminotransferasa con análogos de GABA para el tratamiento de carcinoma hepatocelular
JP6841821B2 (ja) * 2015-10-09 2021-03-10 ノースウェスタン ユニバーシティ てんかん、嗜癖および肝細胞癌の処置のためのｇａｂａアミノトランスフェラーゼ不活性化剤としての（ｓ）−３−アミノ−４−（ジフルオロメチレニル）シクロペント−１−エン−１−カルボン酸および関連化合物
US10632088B2 (en) * 2016-10-10 2020-04-28 Northwestern University Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
EP4692048A3 (en) * 2017-02-08 2026-04-01 Ovid Therapeutics Inc. Methods of treating cdkl5 disorders with the compound ov329
KR20250167147A (ko) * 2018-02-08 2025-11-28 오비드 테라퓨틱스 인크. 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도
MX2020012691A (es) * 2018-05-25 2021-02-15 Univ Northwestern Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico.

Also Published As

Publication number Publication date
CA3095468A1 (en) 2019-10-03
CN112218628A (zh) 2021-01-12
JP2021519753A (ja) 2021-08-12
IL277599A (en) 2020-11-30
AU2019243586A1 (en) 2020-10-15
EP3758693A1 (en) 2021-01-06
US20190298674A1 (en) 2019-10-03
EP3758693A4 (en) 2021-06-02
WO2019191525A1 (en) 2019-10-03
KR20210009306A (ko) 2021-01-26

Similar Documents

Publication Publication Date Title
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
MX2021002321A (es) Nuevos metodos.
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
WO2017087608A8 (en) Modulators of ror-gamma
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
PH12020551427A1 (en) Epinephrine spray formulations
MX2023009631A (es) Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi.
EP4335418A3 (en) Compositions and methods for treating pterygium
MX2024002360A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MX2025001444A (es) Anticuerpos monoclonales anti-trkb y metodos de uso
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
MX2023014484A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
WO2020023094A3 (en) Treatment of lysosomal storage disorders